Compare
Jazz Pharmaceuticals vs Merck & (JAZZ vs MRK)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Jazz Pharmaceuticals (JAZZ) returned +71.1% and Merck & (MRK) +73.9%; so far this year the figures are +38.1% and +39.4%.
Merck & is the larger company by market value, about 24.0 times the size of Jazz Pharmaceuticals.
On trailing earnings, JAZZ trades at 76.5 times and MRK at 149.7 times.
Revenue grew +13.5% at JAZZ and +4.9% at MRK over the last year.
JAZZ pays no dividend. MRK yields 2.32%.
Data as of the latest close. Not investment advice.
Relative performance
| JAZZ | MRK | |
|---|---|---|
| Price | $234.76 | $146.73 |
| 1-day | +3.27% | -0.14% |
| YTD | +38.09% | +39.40% |
| 1 year | +71.08% | +73.87% |
| 3 years | +84.36% | +42.66% |
| Market cap | $15.1B | $361.7B |
| P/E | 76.5 | 149.7 |
| P/S | 3.19 | 5.37 |
| P/B | 3.59 | 8.06 |
| Revenue growth | +13.50% | +4.90% |
| EPS growth | — | -87.10% |
| Gross margin % | — | 71.8 |
| Net margin % | 4.4 | 3.6 |
| ROE % | 4.9 | 5.5 |
| Debt / equity | 1.33 | 1.20 |
| FCF yield % | 10.8 | 4.1 |
| Dividend yield % | — | 2.32 |
| Beta | 0.53 | 0.18 |
| RSI (14) | 60.5 | 51.3 |
| Technical rating |